Search
Ferumoxytol
go.drugbank.com/drugs/DB06215ApprovedInvestigational[L54501] The drug remains approved in the US, with a new indication being approved in October of 2025 for Ferumoxytol's use as a diagnostic agent for MRI of the brain. … [L54506] It is comprised of superparamagnetic iron oxide nanoparticles which are coated by a semi-synthetic carbohydrate shell in an isotonic, neutral pH solution that may be administered at relatively
Categories: Compounds used in a research, industrial, or household settingDalbavancin
go.drugbank.com/drugs/DB06219ApprovedInvestigationalpyogenes, S. agalactiae, S. dysgalactiae, the S. anginosus group (including S. anginosus, S. intermedius, and S. constellatus), and Enterococcus faecalis (vancomycin susceptible strains) [FDA Label, F2356 … Dalbavancin acts by interfering with bacterial cell wall synthesis by binding to the D-alanyl-D-alanine terminus of nascent cell wall peptidoglycan and preventing cross-linking [FDA Label, F2356, A4072
HMR4011
go.drugbank.com/drugs/DB06225ExperimentalHMR4011 (IPL 576,092) is a novel steroidal anti-inflammatory compound with a mechanism of action distinct from that of glucocorticoid. … IPL 576,092 has previously been investigated as a treatment for asthma.
Ridaforolimus
go.drugbank.com/drugs/DB06233InvestigationalCategories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 InhibitorsAvanafil
go.drugbank.com/drugs/DB06237ApprovedAvanafil is a phosphodiesterase-5 (PDE5) inhibitor used in the treatment of erectile dysfunction. … In comparison with other drugs of the same class, it shows greater selectivity for PDE5 over PDE6 than both [sildenafil] and [vardenafil] but less selectivity than [tadalafil], suggesting a relatively
Categories: Cytochrome P-450 Substrates, P-glycoprotein substratesSynonyms: (S)-4-(3-Chloro-4-methoxybenzylamino)-2-(2-hydroxymethylpyrrolidin-1-yl)-N-pyrimidin-2-ylmethyl-5-pyrimidinecarboxamideFluasterone
go.drugbank.com/drugs/DB06250ExperimentalHas antiproliferative effects on HIV-1 and reduces HIV-1 replication.